Sign in
Active, not recruitingPhase 2/3

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

Key facts

Who runs it
M.D. Anderson Cancer Center
Where
Houston and Richmond, United StatesSee the 2 sitesAlso in 1 other country, 1 site
Trial code
Status
Active, not recruiting
Phase
Phase 2/3
People taking part
110 people enrolled
Started
17 Jul 2019
Expected to end
31 Dec 2028
Type of study
Interventional, 4 groups
Treatments tested
  • Haloperidol
  • Lorazepam
  • Placebo
  • Quality-of-Life Assessment
  • Questionnaire Administration
Record updated
15 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • [Patients] Diagnosis of advanced cancer (defined as locally advanced, metastatic recurrent, or incurable disease)
  • [Patients] Admitted to the acute palliative care unit‡
  • [Patients] Delirium as per DSM-5 criteria
  • [Patients] Hyperactive or mixed delirium with RASS ≥1* in the past 24 h despite efforts to treat potential underlying causes
  • [Patients] On scheduled haloperidol for delirium (≤8 mg in the past 24 h) or required ≥4 mg of rescue haloperidol for agitation in the past 24 h
  • [Patients] Age 18 years or older
  • [Caregivers] Patient's spouse, adult child, sibling, parent, other relative, or significant other (partner as defined by patient)
  • [Caregivers] Age 18 years or older

Who cannot take part

  • [Patients] History of myasthenia gravis or acute narrow angle glaucoma
  • [Patients] History of neuroleptic malignant syndrome or active seizure disorder (with seizure episode within the past week)
  • [Patients] History of Parkinson's disease, Alzheimer's or Lewy body dementia
  • [Patients] History of hypersensitivity to haloperidol or lorazepam
  • [Patients] History of prolonged QTc or QTcF interval (>500 ms)† if documented by most recent ECG within the past month
  • [Patients] On scheduled lorazepam within the past 48 h

Where in United States

Also in 1 other country, 1 site

  • M D Anderson Cancer CenterHouston, United States
  • Virginia Commonwealth University/Massey Cancer CenterRichmond, United States

About the trial

What the trial wants to find out

This phase II/IIII trial studies how well haloperidol and lorazepam work in controlling symptoms of persistent agitated delirium in patients with cancer that has spread to other places in the body undergoing palliative care. Haloperidol and lorazepam may help in controlling symptoms of agitated delirium in patients with cancer and may lessen any distress that their caregivers may be experiencing.

The 4 groups in the trial

  • Group I (haloperidol, placebo)Treatment being tested

    Patients receive haloperidol IV over 3-15 minutes every 4 hours and then every hour as needed and placebo IV every 4 hours and then every hour as needed until discharge from palliative care unit.

    Treatment: Haloperidol, Placebo, Quality-of-Life Assessment, and Questionnaire Administration

  • Group II (lorazepam, placebo)Treatment being tested

    Patients receive lorazepam IV over 3-15 minutes every 4 hours and then every hour as needed and placebo IV every 4 hours and then every hour as needed until discharge from palliative care unit.

    Treatment: Lorazepam, Placebo, Quality-of-Life Assessment, and Questionnaire Administration

  • Group III (haloperidol, lorazepam)Treatment being tested

    Patients receive haloperidol IV over 3-15 minutes every 4 hours and then every hour as needed and lorazepam IV over 3-15 minutes every 4 hours and then every hour as needed until discharge from palliative care unit.

    Treatment: Haloperidol, Lorazepam, Quality-of-Life Assessment, and Questionnaire Administration

  • Group IV (placebo, lorazepam)Treatment being tested

    Patients receive two different placebos IV every 4 hours. Patients then receive placebo IV and lorazepam IV over 3-15 minutes every hour as needed until discharge from palliative care unit.

    Treatment: Lorazepam, Placebo, Quality-of-Life Assessment, and Questionnaire Administration

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Strategies for Persistent Agitated Delirium in Palliative Care
Publications
Record updated
15 June 2026